The Asia Pacific Proton Therapy Market is expected to witness market growth of 13.3% CAGR during the forecast period (2022-2028).
High-quality imaging for daily tumor contour assessment, treatment planning software that shows 3D dose distributions, and a variety of system configurations, such as several treatment rooms connected to one accelerator, are all features of modern proton systems. The number of hospitals that offer proton therapy is continuing to increase, in part because of these technological advancements and in part due to the steadily growing body of clinical data related to proton therapy.
A method called FLASH radiation, which uses extremely high dose rates for photon and proton treatments, is currently being developed. If used in a clinical setting, it might reduce the number of treatments needed to just one to three 1-second sessions, further minimizing side effects. While working on the creation of the Harvard Cyclotron Laboratory, Robert R. Wilson submitted a paper in 1946 that contained the initial hypothesis that powerful protons is expected to be a useful treatment (HCL). Particle accelerators constructed for physics research, particularly those at Uppsala in Sweden in 1957 and Berkeley Radiation Laboratory in 1954, were used for the first treatments.
Some of the key factors influencing the regional market include an increase in the prevalence of cancer, an increase in government measures to develop healthcare infrastructure, and a rise in the number of persons predisposed to various chronic diseases. Additionally, the development and approval of products for proton therapy may benefit market growth in advanced countries like Japan. The growing healthcare infrastructure and improved government initiatives is expected to allow regional market participants to increase their offerings and obtain the biggest feasible revenue share.
The China market dominated the Asia Pacific Proton Therapy Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $74,530.9 Thousands by 2028. The Japan market is poised to witness a CAGR of 12.6% during (2022 - 2028). Additionally, The India market is experiencing a CAGR of 14% during (2022 - 2028).
Based on Product Type, the market is segmented into Accelerator, Beam Delivery System, Beam Transport System, Nozzle & Image Viewers and Patient Positioning System. Based on Indication, the market is segmented into CNS Cancer, Prostate Cancer, Head & Neck Cancer, Breast Cancer and Others. Based on End User, the market is segmented into Hospitals, Proton Therapy Centers and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Toshiba Corporation, Siemens Healthineers AG (Siemens AG), Ion Beam Applications SA, Hitachi, Ltd., Mirion Technologies, Inc., Mevion Medical Systems, Inc., Provision Healthcare, Sumitomo Corporation and Optivus Proton Therapy, Inc.
High-quality imaging for daily tumor contour assessment, treatment planning software that shows 3D dose distributions, and a variety of system configurations, such as several treatment rooms connected to one accelerator, are all features of modern proton systems. The number of hospitals that offer proton therapy is continuing to increase, in part because of these technological advancements and in part due to the steadily growing body of clinical data related to proton therapy.
A method called FLASH radiation, which uses extremely high dose rates for photon and proton treatments, is currently being developed. If used in a clinical setting, it might reduce the number of treatments needed to just one to three 1-second sessions, further minimizing side effects. While working on the creation of the Harvard Cyclotron Laboratory, Robert R. Wilson submitted a paper in 1946 that contained the initial hypothesis that powerful protons is expected to be a useful treatment (HCL). Particle accelerators constructed for physics research, particularly those at Uppsala in Sweden in 1957 and Berkeley Radiation Laboratory in 1954, were used for the first treatments.
Some of the key factors influencing the regional market include an increase in the prevalence of cancer, an increase in government measures to develop healthcare infrastructure, and a rise in the number of persons predisposed to various chronic diseases. Additionally, the development and approval of products for proton therapy may benefit market growth in advanced countries like Japan. The growing healthcare infrastructure and improved government initiatives is expected to allow regional market participants to increase their offerings and obtain the biggest feasible revenue share.
The China market dominated the Asia Pacific Proton Therapy Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $74,530.9 Thousands by 2028. The Japan market is poised to witness a CAGR of 12.6% during (2022 - 2028). Additionally, The India market is experiencing a CAGR of 14% during (2022 - 2028).
Based on Product Type, the market is segmented into Accelerator, Beam Delivery System, Beam Transport System, Nozzle & Image Viewers and Patient Positioning System. Based on Indication, the market is segmented into CNS Cancer, Prostate Cancer, Head & Neck Cancer, Breast Cancer and Others. Based on End User, the market is segmented into Hospitals, Proton Therapy Centers and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Toshiba Corporation, Siemens Healthineers AG (Siemens AG), Ion Beam Applications SA, Hitachi, Ltd., Mirion Technologies, Inc., Mevion Medical Systems, Inc., Provision Healthcare, Sumitomo Corporation and Optivus Proton Therapy, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Product Type- Accelerator
- Beam Delivery System
- Beam Transport System
- Nozzle & Image Viewers
- Patient Positioning System
- CNS Cancer
- Prostate Cancer
- Head & Neck Cancer
- Breast Cancer
- Others
- Hospitals
- Proton Therapy Centers
- Others
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Toshiba Corporation
- Siemens Healthineers AG (Siemens AG)
- Ion Beam Applications SA
- Hitachi, Ltd.
- Mirion Technologies, Inc.
- Mevion Medical Systems, Inc.
- Provision Healthcare
- Sumitomo Corporation
- Optivus Proton Therapy, Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. Asia Pacific Proton Therapy Market by Product Type
Chapter 5. Asia Pacific Proton Therapy Market by Indication
Chapter 6. Asia Pacific Proton Therapy Market by End User
Chapter 7. Asia Pacific Proton Therapy Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Toshiba Corporation
- Siemens Healthineers AG (Siemens AG)
- Ion Beam Applications SA
- Hitachi, Ltd.
- Mirion Technologies, Inc.
- Mevion Medical Systems, Inc.
- Provision Healthcare
- Sumitomo Corporation
- Optivus Proton Therapy, Inc.
Methodology
LOADING...
